<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04093453</url>
  </required_header>
  <id_info>
    <org_study_id>18hh4373</org_study_id>
    <nct_id>NCT04093453</nct_id>
  </id_info>
  <brief_title>Propionate and Energy Homeostasis</brief_title>
  <acronym>PROEM</acronym>
  <official_title>The Acute Effect of Propionate on Energy Homeostasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Imperial College London</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The research project aims to examine the effect of a dietary supplement called propionate on
      how the human body in healthy adults aged (18- 65 years) responds to during fasting, exercise
      and following a liquid mixed meal test and how that would affect energy homeostasis and
      substrate oxidation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Dietary fibres have long been recognised for their important role in a healthy diet due to
      their negative association with, and even management of, chronic diseases such as obesity,
      diabetes, metabolic syndrome, cardiovascular disease and inflammatory-bowel disease among
      others.Emerging evidence has suggested that these benefits could largely be attributed to
      short chain fatty acids (SCFA) (acetate, propionate and butyrate), the main by-products of
      fibre fermentation in the gut. Previous research has demonstrated that a long-term elevation
      in the SCFA propionate significantly reduced body weight gain in overweight adults and
      reduced liver fat storage.

      The current project will examine potential mechanisms for the positive effect of propionate
      on energy homeostasis and metabolic profile.The effects of propionate on circulating glucose,
      insulin, gut hormones and lipid levels at rest, following moderate-intensity exercise and
      mixed meal tolerance test will be examined.

      To acutely increase propionate absorption from the gut the present project will use a simple
      nutritional supplement: sodium propionate in a hydroxypropylmethyl cellulose (HPMC) capsule.
      This capsule is coated with an enteric film which prevents gastric digestion until the
      capsule reaches the intestine. This nutritional supplement has been used in human volunteers
      in a previously approved ethics application (12/LO/1769: Oral propionate and glucose
      homeostasis). A 5g acute dose of sodium propionate had previously been tested and reported no
      adverse effects . The MHRA have confirmed that encapsulated sodium propionate is not classed
      as an investigative medicinal product.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 12, 2018</start_date>
  <completion_date type="Actual">August 7, 2019</completion_date>
  <primary_completion_date type="Actual">August 7, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>This protocol consisted of three individual trials. Participants will complete only a single trial.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Participants and investigators will be masked to the contents of the capsules (sodium propionate or sodium chloride). They will not be masked to whether it is a resting or exercise or fasting condition as this is not possible.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in Resting Energy Expenditure</measure>
    <time_frame>6 hours</time_frame>
    <description>Changes in Resting Energy Expenditure between sodium propionate and sodium chloride (control).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in Resting Lipid Oxidation</measure>
    <time_frame>6 hours</time_frame>
    <description>Changes in Resting Lipid Oxidation between sodium propionate and sodium chloride (control).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in Energy Expenditure during Exercise</measure>
    <time_frame>240 minutes</time_frame>
    <description>Changes in Energy Expenditure between sodium propionate and sodium chloride (control) during exercise.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in Lipid Oxidation during Exercise</measure>
    <time_frame>240 minutes</time_frame>
    <description>Changes in Lipid Oxidation between sodium propionate and sodium chloride (control) during exercise.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in Energy Expenditure post-prandially</measure>
    <time_frame>300 minutes</time_frame>
    <description>Changes in Energy Expenditure between sodium propionate and sodium chloride (control) post-prandially.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in Lipid Oxidation post-prandially</measure>
    <time_frame>300 minutes</time_frame>
    <description>Changes in Lipid Oxidation between sodium propionate and sodium chloride (control) post-prandially.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in GLP-1 Concentration</measure>
    <time_frame>360, 240 and 300 minutes</time_frame>
    <description>Changes in GLP-1 concentrations between sodium propionate and sodium chloride (control) during fasting, exercise and post-prandially.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Insulin Concentration</measure>
    <time_frame>360, 240 and 300 minutes</time_frame>
    <description>Changes in insulin concentrations between sodium propionate and sodium chloride (control) during fasting, exercise and post-prandially.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in glucose concentration</measure>
    <time_frame>360, 240 and 300 minutes</time_frame>
    <description>Changes in glucose concentrations between sodium propionate and sodium chloride (control) during fasting, exercise and post-prandially.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in free fatty acid concentration</measure>
    <time_frame>360, 240 and 300 minutes</time_frame>
    <description>Changes in free fatty acid concentrations between sodium propionate and sodium chloride (control) during fasting, exercise and post-prandially.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in subjective nausea</measure>
    <time_frame>360, 240 and 300 minutes</time_frame>
    <description>Changes in subjective nausea between sodium propionate and sodium chloride (control) during fasting, exercise and post-prandially.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in subjective hunger</measure>
    <time_frame>360, 240 and 300 minutes</time_frame>
    <description>Changes in subjective hunger between sodium propionate and sodium chloride (control) during fasting, exercise and post-prandially.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in subjective thirst</measure>
    <time_frame>360, 240 and 300 minutes</time_frame>
    <description>Changes in subjective thirst between sodium propionate and sodium chloride (control) during fasting, exercise and post-prandially.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">49</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Placebo + Fasting</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Sodium Chloride tested in a fasting state. Participants will be fasting for duration of study visit (360 minutes).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + Exercise</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Sodium Chloride tested in an exercise state. Participants will have the placebo then exercise will be performed at 40% of maximal aerobic capacity for one hour.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + Post-prandial</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Sodium Chloride tested in a post-prandial state. Participants will have the placebo then a mixed liquid meal test is given.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Propionate and Fasting</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sodium Propionate tested in a fasting state. Participants will be fasting for duration of study visit (360 minutes).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Propionate and Exercise</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sodium Propionate tested in an exercise state. Participants will have the sodium propionate then exercise will be performed at 40% of maximal aerobic capacity for one hour.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Propionate and Post-prandial</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sodium Propionate tested in a post-prandial state. Participants will have the sodium propionate then a mixed liquid meal test is given.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo (Sodium Chloride)</intervention_name>
    <description>Participant receive Placebo (Sodium Chloride)</description>
    <arm_group_label>Placebo + Exercise</arm_group_label>
    <arm_group_label>Placebo + Fasting</arm_group_label>
    <arm_group_label>Placebo + Post-prandial</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Exercise</intervention_name>
    <description>1 hour exercise</description>
    <arm_group_label>Placebo + Exercise</arm_group_label>
    <arm_group_label>Propionate and Exercise</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Sodium Propionate</intervention_name>
    <description>Participant receive Sodium Propionate</description>
    <arm_group_label>Propionate and Exercise</arm_group_label>
    <arm_group_label>Propionate and Fasting</arm_group_label>
    <arm_group_label>Propionate and Post-prandial</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy volunteers (body mass index (BMI) of 18-35 kg/m2)

          -  Age between 18-65 years (inclusive)

        Exclusion Criteria:

          -  Weight change of â‰¥ 3kg in the preceding 2 months

          -  Current smokers

          -  Substance abuse

          -  Excess alcohol intake

          -  Pregnancy

          -  Diabetes

          -  Cardiovascular disease

          -  Cancer

          -  Gastrointestinal disease e.g. inflammatory bowel disease or irritable bowel syndrome

          -  Kidney disease

          -  Liver disease

          -  Pancreatitis

          -  Started new medication within the last 3 months likely to interfere with energy
             metabolism, appetite regulation and hormonal balance, including: anti-inflammatory
             drugs or steroids, antibiotics, androgens, phenytoin, erythromycin or thyroid
             hormones.

          -  Involved in current research or have recently been involved in any research prior to
             recruitment in the past 12 weeks.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edward Chambers, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Imperial College London</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gary Frost, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Imperial College London</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Imperial Clinical Research Facility</name>
      <address>
        <city>London</city>
        <zip>W12 0HS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>August 5, 2019</study_first_submitted>
  <study_first_submitted_qc>September 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 18, 2019</study_first_posted>
  <last_update_submitted>October 11, 2019</last_update_submitted>
  <last_update_submitted_qc>October 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Short Chain Fatty Acids</keyword>
  <keyword>Propionate</keyword>
  <keyword>Energy Expenditure</keyword>
  <keyword>Lipid Oxidation</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>There is not a plan to make IPD available</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

